Compare Brown-Forman Corporation Class B (BF.B) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs GSK plc — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Brown-Forman Corporation Class B pays none. Which is the better fit depends on your goals.
| BF.B | GSK | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $61.18 |
52-Week Low | $22.80 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $27.92, down 0.96% with mixed technical signals showing bullish moving averages but neutral oscillators. The stock has demonstrated earnings momentum with three consecutive quarterly beats, though analyst coverage remains divided with a 25% buy rating. Recent price action shows consolidation around the $28 pivot point level.
The outlook remains cautiously optimistic given strong recent earnings performance, though limited analyst coverage and divided sentiment suggest moderate risk. Upside potential exists if earnings momentum continues, while downside risks include market volatility and potential execution challenges in maintaining growth trajectory.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
